Ctrl

K

Meprobamate

Class
Hypnotics and sedatives
Subclass
Carbamates
Substance name
Meprobamate
Common formulations
Tablet
Indications for use
Labeled indications
Adults
•
Treatment of anxiety disorders
Children
•
Treatment of anxiety disorders
Safety risks
Contraindications
A known hypersensitivity to Meprobamate
Pre-existing porphyria
Warnings and precautions
Drug abuse
•
Use caution with a personal or family history of drug or substance abuse.
Respiratory depression
•
Use caution with respiratory disease.
Seizures
•
Use caution with a history of seizure disorder.
Suicidal ideation
•
Use caution with depression or suicidal tendencies.
Specific populations
Renal impairment
eGFR 10-50 mL/min/1.73 m²
•
Use with caution. Do not exceed frequency of q9-12h. Monitor ECG. Monitor for hypotension and gastrointestinal symptoms.
eGFR < 10 mL/min/1.73 m²
•
Use with caution. Do not exceed frequency of q12-18h. Monitor ECG. Monitor for hypotension and gastrointestinal symptoms.
Renal replacement therapy
Continuous renal replacement
•
Maximal frequency of q9-12h. Monitor electrocardiogram. Monitor for hypotension and gastrointestinal symptoms.
Intermittent hemodialysis
•
Maximal frequency of q12-18h. Monitor electrocardiogram. Monitor for hypotension and gastrointestinal symptoms.
Peritoneal dialysis
•
Maximal frequency of q12-18h. Monitor electrocardiogram. Monitor for hypotension and gastrointestinal symptoms.
Hepatic impairment
Any severity
•
Use with caution.
Pregnancy and breastfeeding
Pregnancy
All trimesters • Australia Category: C
•
Avoid use. Evidence of fetal harm in humans. An increased risk of congenital malformations has been associated with minor tranquilizers including this drug, especially during the first trimester of pregnancy.
•
Use should be avoided especially during the first trimester.
•
Women of childbearing potential should be advised of risks.
Breastfeeding
Acceptable for use during breastfeeding.
•
Consider alternative agents that may be safer.
Low excretion in breastmilk (5-25%).
Unknown drug levels in breastfed infants.
No overt adverse effects reported in breastfed infants.
Some adverse effects on lactation reported.
Acceptable for use during breastfeeding.
Low excretion in breastmilk (5-25%).
Unknown drug levels in breastfed infants.
Unlikely to cause adverse effects in breastfed infants.
Some adverse effects on lactation reported.
Adverse reactions
Unknown frequency
•
Acute intermittent porphyria, agranulocytosis, anaphylaxis, anuria, aplastic anemia, ataxia, bronchospasm, cardiac arrhythmias, ↓ platelet count, EEG abnormalities, erythema multiforme, erythroderma, hypotension, proctitis, asthenia, chills, diarrhea, dizziness, euphoria, itching, nausea, palpitations, paresthesia, seizure, skin rash, somnolence, syncope, vertigo, vomiting, speech disturbance, Stevens-Johnson syndrome, stomatitis, tachycardia
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource